Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency is a genetic disorder that results in low levels of a protein called alpha-1 antitrypsin, which can lead to lung and liver diseases.
Alpha-1 Antitrypsin Deficiency: Fazirsiran Treatment Study
We are investigating the long-term safety of fazirsiran for people with liver disease related to Alpha-1 Antitrypsin Deficiency. The study will also look at how this treatment affects liver health over time.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have any chronic liver diseases like hepatitis B or C, liver cancer, or autoimmune hepatitis?
- Are you currently pregnant, breastfeeding, or planning to become pregnant during the study?
- Are you likely to need major surgery that requires at least one night in the hospital?
- Have you had any major complications or serious side effects from previous study treatments?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Fazirsiran
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Vienna
Department of Medicine III, Division of Gastroenterology and Hepatology
Vienna, Austria
Universitaetsklinikum Aachen AöR
Medizinische Klinik III
Vaals, Germany
Servico de Saude da RAM EPERAM
Gastroenterology
São Martinho, Portugal
Sponsor: Takeda Development Center Americas Inc.
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.